ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics (www.retro-sense.com) announced today that it has been identified and selected by Windhover (Elsevier Business Intelligence) as a “Top Project to Watch: Most Licensable Products.” RetroSense Therapeutics is a privately held biotechnology company at the forefront of developing optogenetic therapies for vision restoration. The Top Projects to Watch are “hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products." "Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said David Cassak, Vice President, Content, Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”
Help employers find you! Check out all the jobs and post your resume.
